A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
65–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\>/= 65 years old
documented diagnosis of lung, breast, or ovarian cancer, or NHL
scheduled to receive one of 15 standard chemotherapy regimens
chemotherapy naive OR have received adjuvant therapy AND/OR have no more than one regimen of chemotherapy for metastatic disease
life expectancy of at least 3 months
ECOG performance status \</=2
adequate renal and hematologic function
informed consent for participation in the study prior to any study specific procedures
unstable/uncontrolled cardiac conditions or hypertension
active infection
subject is currently enrolled or has not yet completed at least 30 days since ending other investigational device or drug trial or is receiving other investigational agents
You may not be if
known hypersensitivity to any of the products to be administered during dosing
primary prophylactic antibiotics in all cycles
prior radiation therapy within 2 weeks of randomization into this study or plan for radiation therapy during study participation, except for spot radiation for bony metastases
prior bone marrow or stem cell transplant or plan to receive any transplant therapy during study participation
clinically symptomatic brain metastases
Folstein mini-mental state exam score \<18
Any premalignant myeloid condition or any malignancy with myeloid characteristics
Clareo Health | A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
